Publications

Found 1 results
Filters: Author is E.F. Rodrigues  [Clear All Filters]
2013
A. L. Mencalha, Rodrigues, E. F., Abdelhay, E., and Fernandez, T. S., Accurate monitoring of promoter gene methylation with high-resolution melting polymerase chain reaction using the ABCB1 gene as a model, vol. 12, pp. 714-722, 2013.
Abolhoda A, Wilson AE, Ross H, Danenberg PV, et al. (1999). Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin. Cancer Res. 5: 3352-3356. PMid:10589744   Ando T, Nishimura M and Oka Y (2000). Decitabine (5-Aza-2'-deoxycytidine) decreased DNA methylation and expression of MDR-1 gene in K562/ADM cells. Leukemia 14: 1915-1920. http://dx.doi.org/10.1038/sj.leu.2401914 PMid:11069027   Baker EK, Johnstone RW, Zalcberg JR and El-Osta A (2005). Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. Oncogene 24: 8061-8075. http://dx.doi.org/10.1038/sj.onc.1208955 PMid:16091741   Chen KG and Sikic BI (2012). Molecular pathways: regulation and therapeutic implications of multidrug resistance. Clin. Cancer Res. 18: 1863-1869. http://dx.doi.org/10.1158/1078-0432.CCR-11-1590 PMid:22344233 PMCid:3359695   El-Osta A, Kantharidis P, Zalcberg JR and Wolffe AP (2002). Precipitous release of methyl-CpG binding protein 2 and histone deacetylase 1 from the methylated human multidrug resistance gene (MDR1) on activation. Mol. Cell Biol. 22: 1844-1857. http://dx.doi.org/10.1128/MCB.22.6.1844-1857.2002 PMid:11865062 PMCid:135609   Goldie JH and Coldman AJ (1984). The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Res. 44: 3643-3653. PMid:6744284   Hon GC, Hawkins RD, Caballero OL, Lo C, et al. (2012). Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer. Genome Res. 22: 246-258. http://dx.doi.org/10.1101/gr.125872.111 PMid:22156296 PMCid:3266032   Jin S and Scotto KW (1998). Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y. Mol. Cell Biol. 18: 4377-4384. PMid:9632821 PMCid:109021   Kantharidis P, El-Osta A, deSilva M, Wall DM, et al. (1997). Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance. Clin. Cancer Res. 3: 2025-2032. PMid:9815593   Kim SN, Kim NH, Lee W, Seo DW, et al. (2009). Histone deacetylase inhibitor induction of P-glycoprotein transcription requires both histone deacetylase 1 dissociation and recruitment of CAAT/enhancer binding protein beta and pCAF to the promoter region. Mol. Cancer Res. 7: 735-744. http://dx.doi.org/10.1158/1541-7786.MCR-08-0296 PMid:19435809   Kuo MT, Vyas RC, Jiang LX and Hittelman WN (1994). Chromosome breakage at a major fragile site associated with P-glycoprotein gene amplification in multidrug-resistant CHO cells. Mol. Cell Biol. 14: 5202-5211. PMid:7913517 PMCid:359039   Kusaba H, Nakayama M, Harada T, Nomoto M, et al. (1999). Association of 5' CpG demethylation and altered chromatin structure in the promoter region with transcriptional activation of the multidrug resistance 1 gene in human cancer cells. Eur. J. Biochem. 262: 924-932. http://dx.doi.org/10.1046/j.1432-1327.1999.00469.x PMid:10411657   Li LC and Dahiya R (2002). MethPrimer: designing primers for methylation PCRs. Bioinformatics 18: 1427-1431. http://dx.doi.org/10.1093/bioinformatics/18.11.1427 PMid:12424112   Nakayama M, Wada M, Harada T, Nagayama J, et al. (1998). Hypomethylation status of CpG sites at the promoter region and overexpression of the human MDR1 gene in acute myeloid leukemias. Blood 92: 4296-4307. PMid:9834236   Reed K, Hembruff SL, Sprowl JA and Parissenti AM (2010). The temporal relationship between ABCB1 promoter hypomethylation, ABCB1 expression and acquisition of drug resistance. Pharmacogenomics J. 10: 489-504. http://dx.doi.org/10.1038/tpj.2010.1 PMid:20125118   Suzuki MM and Bird A (2008). DNA methylation landscapes: provocative insights from epigenomics. Nat. Rev. Genet. 9: 465-476. http://dx.doi.org/10.1038/nrg2341 PMid:18463664   Toyota M, Kopecky KJ, Toyota MO, Jair KW, et al. (2001). Methylation profiling in acute myeloid leukemia. Blood 97: 2823-2829. http://dx.doi.org/10.1182/blood.V97.9.2823 PMid:11313277   Ueda K, Pastan I and Gottesman MM (1987). Isolation and sequence of the promoter region of the human multidrug-resistance (P-glycoprotein) gene. J. Biol. Chem. 262: 17432-17436. PMid:2891692   Wise JG (2012). Catalytic transitions in the human MDR1 P-glycoprotein drug binding sites. Biochemistry 51: 5125-5141. http://dx.doi.org/10.1021/bi300299z PMid:22647192 PMCid:3383123   Wittwer CT, Reed GH, Gundry CN, Vandersteen JG, et al. (2003). High-resolution genotyping by amplicon melting analysis using LCGreen. Clin. Chem. 49: 853-860. http://dx.doi.org/10.1373/49.6.853 PMid:12765979   Wojdacz TK and Dobrovic A (2007). Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res. 35: e41. http://dx.doi.org/10.1093/nar/gkm013 PMid:17289753 PMCid:1874596   Wojdacz TK, Borgbo T and Hansen LL (2009). Primer design versus PCR bias in methylation independent PCR amplifications. Epigenetics 4: 231-234. PMid:19483476